Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Unicycive Therapeutics Inc. Common Stock
UNCY | US
7.23
USD-0.37
-4.87%
UNCY | US
About Unicycive Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
7.23
Open
7.82
High
7.84
Low
7.20
Unicycive Therapeutics Inc. a biotechnology company engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494 which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos California.
View LessUNCY | US
Risk
66.5
Sharpe
0.21
Luna's Score
37/100
Recommendation
Sell
Luna says (UNCY | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
87.1%1 month
66.5%3 months
60.9%6 months
65.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.89
Debt to equity
-3.15
Debt to assets
1.05
Ent. to EBITDA
-1.03
Ent. to rev.
47.00
PEG
-
Other Fundamentals
EBITDA
-28.84M
MarketCap
682.20M
MarketCap(USD)
682.20M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-121.76
Short ratio
0.60
Short perc.
1.14
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.51
Range1M
1.85
Range3M
2.69
Volumes: Market Activity
Rel. volume
1.25
Price X volume
6.52M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.03 | - | Cheaper |
| Ent. to Revenue | 47.00 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.89 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 60.94 | - | Par |
| Debt to Equity | -3.15 | -1.23 | Cheaper |
| Debt to Assets | 1.05 | 0.25 | Expensive |
| Market Cap | 682.20M | - | Emerging |
